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On December 31, 2019, several cases of pneumonia of unknown etiology were reported in Wuhan, China. The outbreak had started in early December or November ([@bib21]), and the number of cases rose quickly; more than 80,000 infections were reported in China as of March 15, 2020, including more than 3,000 deaths. At the time of this review (April 6, 2020), the disease, termed COVID-19 (coronavirus disease 2019), had become pandemic and spread to more than 203 countries and territories, including community transmission in countries like the United States, Germany, France, Spain, Japan, Singapore, South Korea, Iran, and Italy and a large-scale outbreak with more than 600 cases on the cruise ship *Diamond Princess*. As of April 1, more than 870,000 cases and 43,000 deaths had been reported globally, with rapid growth of numbers in many countries. The causative agent of the outbreak was swiftly identified as betacoronavirus with a genomic sequence closely related to that of the severe acute respiratory syndrome (SARS) coronavirus from 2003, earning the new virus the name SARS-CoV-2 ([@bib17], [@bib54], [@bib58], [@bib60]). SARS-CoV-2 likely originated in bats but might have been amplified in an intermediate host. Initial work showed that it can use angiotensin-converting enzyme 2 (ACE2) from bats, civet cats, swine, cats, ferrets, non-human primates (NHPs), and humans as a receptor ([@bib29], [@bib49], [@bib58]). Transmission of the infection to a pet dog in Hong Kong suggests that canine ACE2 can also be recognized by SARS-CoV-2. Pangolins, protected animals that are traded illegally in Asia and elsewhere, have been proposed as a potential amplifying host by some studies ([@bib26], [@bib57]). The initial reports from China and elsewhere note that although most COVID-19 cases present mild to moderate pathology, approximately 20% percent of cases are severe ([@bib9], [@bib18], [@bib21], [@bib43], [@bib50]). The case fatality rate (CFR) seems to be age dependent, with a higher percentage in the elderly, especially men, and an overall interim CFR of approximately 1%--3%. The number of individuals with undetected, mild cases could be much higher than the official case number, which would lead to a lower infection fatality rate (IRF). South Korea, a country that put a massive effort into testing and has already tested tens of thousands of samples, reports much lower CFRs than countries without extensive testing like Spain, Iran, or the United States. The CFR is disproportionally high in Italy (currently 7.3%), likely because of a large number of mild cases missed combined with a relatively older population and a healthcare system that is overwhelmed with cases. The reproductive number (R~0~) of the infection, that is, the number of cases directly generated by one case in a population in which all individuals are susceptible to infection, is estimated to be 2--3 ([@bib30]). Given the severity of the disease, which in most age groups is above that of seasonal influenza or pandemic H1N1 (2009) influenza, vaccines and therapeutics to tackle this novel virus are urgently needed.

Coronaviruses, in Brief {#sec1.1}
-----------------------

SARS-CoV-2 is part of the *Coronaviridae* family, whose members are named after their crown-like appearance under the electron microscope caused by the surface glycoproteins that decorate the virus. The family includes two subfamilies: *Letovirinae* and *Orthocoronavirinae*. *Orthocoronavirinae* includes the genera *Alphacoronvirus*, *Betacoronavirus*, *Gammacoronavirus*, and *Deltacoronavirus*. Alphacoronaviruses and betacoronaviruses typically infect only mammals, whereas gammacoronoviruses and deltacoronaviruses typically infect avian species and sometimes mammals ([@bib12]). Coronaviruses are common human pathogens; two types of alphacoronaviruses (229E and NL63) and two types of betacoronaviruses (OC43 and HKU1) circulate in humans and cause common cold. More pathogenic coronaviruses for humans include SARS-CoV-1, the Middle Eastern respiratory syndrome coronavirus (MERS-CoV), and now SARS-CoV-2, which are all betacoronaviruses.

Coronaviruses have a large (30+ kb) single-stranded positive-sense RNA genome encoding for several open reading frames. One frame encodes the spike protein (S protein), a class I fusion protein that mediates attachment of the virus to cell surface receptors followed by uptake into endosomes (for most coronaviruses). Proteolytic cleavage of the S protein and fusion of viral and endosomal membranes trigger release of viral RNA into the cytosol (reviewed in [@bib16]). The RNA contains a 5′ cap structure and a 3′ poly(A) tail that allows expression of the replicase, which is encoded by approximately two-thirds of the genome. The other third codes for the structural and accessory proteins. The replicase is expressed as two polyproteins: pp1a and pp1ab; these include up to 16 nonstructural proteins (nsps). The nsps are generated by processing of pp1a and pp1ab by 2--3 viral proteases encoded within the replicase. Many nsps then assemble into the replicase-transcriptase complex that---in the host cell cytosol---produces anti-sense genome, new viral genome, and subgenomic RNA that serves as mRNA. Structural proteins S, matrix (M) protein, and envelope (E) are then generated and inserted into the endoplasmatic reticulum and follow the secretory pathway to the endoplasmic reticulum-Golgi intermediate compartment (ERGIC). A minority of coronaviruses also encode a hemagglutinin esterase (HE). In many coronaviruses, the S protein is cleaved into two subunits, S1 and S2, often by furin-like proteases. The RNA genome associates with nucleoprotein and then buds into the ERGIC, forming virus particles. After assembly, virions are transported to the cell surface in vesicles and are exocytosed. Several accessory proteins, which seem to be important for pathogenesis, are also expressed but not all are functionally characterized.

Therapeutics for SARS-CoV-2 Infections {#sec1.2}
--------------------------------------

Clinical trials with the nucleotide analog remdesivir (ClinicalTrials.gov: [NCT04257656](NCT04257656){#intref0010}, [NCT04252664](NCT04252664){#intref0015}, [NCT04280705](NCT04280705){#intref0020}, etc.) and protease inhibitors (ClinicalTrials.gov: [NCT04255017](NCT04255017){#intref0025}, [NCT04276688](NCT04276688){#intref0030}, etc.), as well as other treatment options, are ongoing in China and the United States, and trial results are expected within weeks. Remdesivir works against coronaviruses closely related to SARS-CoV-2 in animal models, as well as against the related MERS-CoV, including in NHPs ([@bib1], [@bib6], [@bib13], [@bib41], [@bib42]). Remdesivir was also tested for treatment of ebolavirus infections in humans (and found to be less successful than other treatments by [@bib36]); therefore, safety data exist for this therapeutic agent, which should accelerate the process of clinical testing against SARS-CoV-2. Remdesivir's mechanism of action as a nucleotide analog is not clear, but it likely terminates RNA synthesis, leads to incorporation mutagenesis, or both ([@bib1]). In addition, a combination of the two licensed HIV inhibitors, lopinavir and ritonavir, is also being tested in clinical trials (e.g., ClinicalTrials.gov: [NCT04264858](NCT04264858){#intref0035}, etc.). Lopinavir is a bona fide protease inhibitor, whereas ritonavir was initially designed as protease inhibitor but was found to boost the half-life of lopinavir by inhibiting cytochrome P450 ([@bib22]). The combination was compassionately used as treatment for SARS-CoV-1 in 2003--2004 and showed some promise ([@bib11]). Effectiveness of the combination was limited in mice but appreciable in NHP models of MERS-CoV ([@bib8], [@bib42]). The mechanism of action of lopinavir is not clear, but it likely inhibits one or more coronavirus proteases. Other treatment options with ongoing or planned clinical trials include dosing recombinant human ACE2 to neutralize the virus and prevent lung damage (ClinicalTrials.gov: [NCT04287686](NCT04287686){#intref0040}) and using the antiviral arbidol, a fusion inhibitor ([@bib24], [@bib44]). Another interesting option is the use of convalescent serum as treatment; clinical trials to test this are ongoing in China (ClinicalTrials.gov: [NCT04264858](NCT04264858){#intref0045}, placebo control, not recruiting yet), and compassionate use of this strategy has recently started in the US (e.g. at Mount Sinai Medical Center, NY). Similarly, polyclonal human immunoglobulin G (IgG) derived from transgenic cows could be used, because this strategy has been successful for MERS-CoV in animal models ([@bib34]) and has been tested for safety in clinical trials (ClinicalTrials.gov: [NCT02788188](NCT02788188){#intref0050}). Many of these trials will have results within months, and if remdesivir (produced by Gilead) and/or lopinavir plus ritonavir (produced by AbbVie as Kaletra and Aluvia, respectively) show effectiveness, they could potentially be used widely within a short time frame. Compassionate use of these drugs has already been reported for SARS-CoV-2 infections ([@bib19], [@bib31]).

What Do We Know about Betacoronavirus Vaccine Design? {#sec1.3}
-----------------------------------------------------

During the 2009 H1N1 influenza virus pandemic, vaccine producers switched their production pipelines quickly from producing trivalent seasonal influenza virus vaccines to monovalent pandemic vaccines. This was basically just a change of strains and established and approved processes, established release criteria, and existing correlates of protection could be used ([@bib25]). Still, it took six months until the vaccine was ready to be distributed and used, and it came too late to affect the second pandemic wave, which took place in the United States in fall 2009. This time, we are facing a new challenge in the form of a virus that has just emerged in humans, and the response will be more complex because there are no existing vaccines or production processes for coronavirus vaccines.

Vaccine technology has significantly evolved in the last decade, including the development of several RNA and DNA vaccine candidates, licensed vectored vaccines (e.g., Ervebo, a vesicular stomatitis virus \[VSV\]-vectored ebolavirus vaccine, licensed in the European Union), recombinant protein vaccines (e.g., Flublok, an influenza virus vaccine made in insect cells, licensed in the United States), and cell-culture-based vaccines (e.g., Flucelvax, an influenza virus vaccine made in mammalian cells). SARS-CoV-2 was identified in record time, and its genomic sequence was swiftly made widely available by Chinese researchers ([@bib54], [@bib58], [@bib60]). In addition, we know from studies on SARS-CoV-1 and the related MERS-CoV vaccines that the S protein on the surface of the virus is an ideal target for a vaccine. In SARS-CoV-1 and SARS-CoV-2, this protein interacts with the receptor ACE2, and antibodies targeting the spike can interfere with this binding, thereby neutralizing the virus ([Figure 1](#fig1){ref-type="fig"} ). The structure of the S protein of SARS-CoV-2 was solved in record time at high resolution, contributing to our understanding of this vaccine target ([@bib27], [@bib53]). Therefore, we have a target antigen that can be incorporated into advanced vaccine platforms.Figure 1Overview of Potential SARS-CoV-2 Vaccine PlatformsThe structure of a coronavirus particle is depicted on the left, with the different viral proteins indicated. The S protein is the major target for vaccine development. The spike structure shown is based on the trimeric SARS-CoV-1 spike (PDB: [5XL3](pdb:5XL3){#intref0070}). One trimer is shown in dark blue, and the receptor binding domain, a main target of neutralizing antibodies, is highlighted in purple. The other two trimers are shown in light blue. SARS-CoV-2 vaccine candidates based on different vaccine platforms have been developed, and for some of them, pre-clinical experiments have been initiated. For one mRNA-based candidate, a clinical trial recently started to enroll volunteers shortly (ClinicalTrials.gov: [NCT04283461](NCT04283461){#intref0075}). However, many additional steps are needed before these vaccines can be used in the population, and this process might take months, if not years. ^1^For some candidates, cGMP processes have already been established. ^2^Clinical trial design might be altered to move vaccines through clinical testing quicker.

Several vaccines for SARS-CoV-1 were developed and tested in animal models, including recombinant S-protein-based vaccines, attenuated and whole inactivated vaccines, and vectored vaccines ([@bib38]). Most of these vaccines protect animals from challenge with SARS-CoV-1, although many do not induce sterilizing immunity. In some cases, vaccination with the live virus results in complications, including lung damage and infiltration of eosinophils in a mouse model (e.g., [@bib5], [@bib48]) and liver damage in ferrets (e.g., [@bib52]). In another study, vaccination with inactivated SARS-CoV-1 led to enhancement of disease in one NHP, whereas it protected 3 animals from challenge ([@bib51]). The same study identified certain epitopes on the S protein as protective, whereas immunity to others seemed to be enhancing disease. However, in almost all cases, vaccination is associated with greater survival, reduced virus titers, and/or less morbidity compared with that in unvaccinated animals. Similar findings have been reported for MERS-CoV vaccines ([@bib2], [@bib20]). Therefore, whereas vaccines for related coronaviruses are efficacious in animal models, we need to ensure that the vaccines, which are developed for SARS-CoV-2, are sufficiently safe.

Another consideration for effective coronavirus vaccine development might be waning of the antibody response. Infection with human coronaviruses does not always induce long-lived antibody responses, and re-infection of an individual with the same virus is possible after an extended period of time (but only in a fraction of individuals and resulting in mild or no symtpoms), as shown in human challenge studies ([@bib7]). Antibody titers in individuals that survived SARS-CoV-1 or MERS-CoV infections often waned after 2--3 years ([@bib33], [@bib55]) or were weak initially ([@bib10]). Despite that, re-infections are unlikely in the short term. Of note, re-infections after days of recovery have been reported recently but appear to be the consequences of false negative test results ([@bib28]). However, they could happen when humoral immunity wanes over months and years. An effective SARS-CoV-2 vaccine will need to overcome these issues to protect in a scenario in which the virus becomes endemic and causes recurrent seasonal epidemics.

SARS-CoV-2 infection causes the most severe pathology in individuals above 50 years of age. The reason for this is not clear, but many viral infections have milder manifestations in naive younger individuals than in naive older individuals. Because older individuals are more affected, it will be important to develop vaccines that protect this segment of the population. Unfortunately, older individuals typically respond less well to vaccination because of immune senescence ([@bib39]). For influenza, which is problematic for older adults, specific formulations for this segment of the population include more antigen or an adjuvant ([@bib14], [@bib47]). Protection in older individuals appears to require higher neutralization titers against influenza virus than in younger individuals ([@bib4]), and this issue might need to be addressed for SARS-CoV-2. If vaccination in older individuals is not effective, they could still benefit indirectly if vaccination is able to stop transmission of the virus in younger individuals.

Only a small number of SARS-CoV-1 vaccines made it to phase I clinical trials before funding dried up because of eradication of the virus from the human population through non-pharmaceutical interventions when case numbers were still small. Results from these trials, performed with an inactivated virus vaccine and a spike-based DNA vaccine, are encouraging because the vaccines were safe and induced neutralizing antibody titers ([@bib32], [@bib35]). Some neutralizing monoclonal antibodies isolated against SARS-CoV-1, like CR3022 ([@bib45], [@bib46]), can cross-react to the receptor binding domain of SARS-CoV-2. This suggests that SARS-CoV-1 vaccines might cross-protect against SARS-CoV-2. However, because these vaccines have not been developed further than phase I, they are currently not available for use. Vaccines against MERS-CoV, also targeting the MERS-CoV S protein, are in pre-clinical and clinical development, including vaccines based on modified vaccinia Ankara vectors, adenovirus vectors, and DNA-based vaccines, and several of them are supported by the Coalition for Epidemic Preparedness Innovation (CEPI) ([@bib56]). However, it is unlikely that MERS-CoV vaccines induce strong cross-neutralizing antibodies to SARS-CoV-2 because of the phylogenetic distance between the two viruses. Nevertheless, we can still learn a lot from these vaccines about how to move forward with SARS-CoV-2 vaccine design ([@bib37]).

The Current Pipeline for SARS-CoV-2 Vaccines {#sec1.4}
--------------------------------------------

The development of vaccines for human use can take years, especially when novel technologies are used that have not been extensively tested for safety or scaled up for mass production. Because no coronavirus vaccines are on the market and no large-scale manufacturing capacity for these vaccines exists as yet ([Table 1](#tbl1){ref-type="table"} ), we will need to build these processes and capacities. Doing this for the first time can be tedious and time consuming ([Figure 1](#fig1){ref-type="fig"}). CEPI has awarded funds to several highly innovative players in the field, and many of them will likely succeed in eventually making a SARS-CoV-2 vaccine. However, none of these companies and institutions have an established pipeline to bring such a vaccine to late-stage clinical trials that allow licensure by regulatory agencies, and they do not currently have the capacity to produce the number of doses needed. An mRNA-based vaccine, which expresses target antigen *in vivo* in the vaccinee after injection of mRNA encapsulated in lipid nanoparticles, co-developed by Moderna and the Vaccine Research Center at the National Institutes of Health, is currently the furthest along, and a phase I clinical trial recently started (ClinicalTrials.gov: [NCT04283461](NCT04283461){#intref0055}). Curevac is working on a similar vaccine but is still in the pre-clinical phase. Additional approaches in the pre-clinical stage include recombinant-protein-based vaccines (focused on the S protein, e.g., ExpresS2ion, iBio, Novavax, Baylor College of Medicine, University of Queensland, and Sichuan Clover Biopharmaceuticals), viral-vector-based vaccines (focused on the S protein, e.g., Vaxart, Geovax, University of Oxford, and Cansino Biologics), DNA vaccines (focused on the S protein, e.g., Inovio and Applied DNA Sciences), live attenuated vaccines (Codagenix with the Serum Institute of India, etc.), and inactivated virus vaccines ([Figure 1](#fig1){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). All of these platforms have advantages and disadvantages ([Table 1](#tbl1){ref-type="table"}), and it is not possible to predict which strategy will be faster or more successful. Johnson & Johnson (J&J) ([@bib23]) and [@bib40] recently joined efforts to develop SARS-CoV-2 vaccines. However, J&J is using an experimental adenovirus vector platform that has not yet resulted in a licensed vaccine. Sanofi's vaccine, to be made using a process similar to the process used for their approved Flublok recombinant influenza virus vaccine ([@bib59]), is also months, if not years, from being ready for use in the human population.Table 1Overview of Vaccine Production Platforms and Technologies for SARS-CoV-2PlatformTargetExisting, Licensed Human Vaccines Using the Same PlatformAdvantagesDisadvantagesRNA vaccinesS proteinNoNo infectious virus needs to be handled, vaccines are typically immunogenic, rapid production possible.Safety issues with reactogenicity have been reported.DNA vaccinesS proteinNoNo infectious virus needs to be handled, easy scale up, low production costs, high heat stability, tested in humans for SARS-CoV-1, rapid production possible.Vaccine needs specific delivery devices to reach good immunogenicity.Recombinant protein vaccinesS proteinYes for baculovirus (influenza, HPV) and yeast expression (HBV, HPV)No infectious virus needs to be handled, adjuvants can be used to increase immunogenicity.Global production capacity might be limited. Antigen and/or epitope integrity needs to be confirmed. Yields need to be high enough.Viral vector-based vaccinesS proteinYes for VSV (Ervebo), but not for other viral vectored vaccinesNo infectious virus needs to be handled, excellent preclinical and clinical data for many emerging viruses, including MERS-CoV.Vector immunity might negatively affect vaccine effectiveness (depending on the vector chosen).Live attenuated vaccinesWhole virionYesStraightforward process used for several licensed human vaccines, existing infrastructure can be used.Creating infectious clones for attenuated coronavirus vaccine seeds takes time because of large genome size. Safety testing will need to be extensive.Inactivated vaccinesWhole virionYesStraightforward process used for several licensed human vaccines, existing infrastructure can be used, has been tested in humans for SARS-CoV-1, adjuvants can be used to increase immunogenicity.Large amounts of infectious virus need to be handled (could be mitigated by using an attenuated seed virus). Antigen and/or epitope integrity needs to be confirmed.

Understanding the Time Frames {#sec1.5}
-----------------------------

Why does this take so long? As mentioned earlier, there are currently no approved human coronavirus vaccines. In addition, many technologies used (production platforms, vectors, etc.) are new and need to be tested thoroughly for safety. The target for the vaccine, the S protein, has been identified, and vaccine candidates are being generated. This is usually followed by two important steps that are typically needed before bringing a vaccine into clinical trials. First, the vaccine is tested in appropriate animal models to see whether it is protective. However, animal models for SARS-CoV-2 might be difficult to develop. The virus does not grow in wild-type mice and only induced mild disease in transgenic animals expressing human ACE2 ([@bib3]). Other potential animal models include ferrets and NHPs, for which pathogenicity studies are ongoing. Even in the absence of an animal model that replicates human disease, it is possible to evaluate the vaccine because serum from vaccinated animals can be tested in *in vitro* neutralization assays. Post-challenge safety data should also be collected in these cases to assess for complications such as the ones seen SARS-CoV-1 and MERS-CoV vaccines. Second, vaccines need to be tested for toxicity in animals, e.g., in rabbits. Usually, viral challenge is not part of this process, because only the safety of the vaccine will be evaluated. This testing, which has to be performed in a manner compliant with GLP (Good Laboratory Practice), typically takes 3--6 months to complete. For some vaccine platforms, parts of the safety testing might be skipped if there is already sufficient data available for similar vaccines made in the same production process.

Vaccines for human use are produced in processes that comply with current Good Manufacturing Practice (cGMP) to ensure constant quality and safety of vaccines. This requires dedicated facilities, trained personnel, proper documentation, and raw material that was produced to be of cGMP quality. These processes have to be designed or amended to fit SARS-CoV-2 vaccines. For many vaccine candidates in the preclinical phase, such processes do not yet exist and have to be developed from scratch.

Once sufficient pre-clinical data are available and initial batches of the vaccine have been produced that are of cGMP quality, clinical trials might be initiated. Typically, clinical development of vaccines starts with small phase I trials to evaluate the safety of vaccine candidates in humans. These are followed by phase II trials (formulation and doses are established to initially prove efficacy) and finally by phase III trials, in which the efficacy and safety of a vaccine need to be demonstrated in a larger cohort. However, in an extraordinary situation like the current one, this scheme might be compressed and an accelerated regulatory approval pathway might be developed. If efficacy is shown, a vaccine might be licensed by regulatory agencies.

Another important point is that production capacity to produce sufficient amounts of cGMP-quality vaccine needs to be available. For vaccines based on existing vaccine platforms, e.g., inactivated or live attenuated vaccines, this can be relatively easily achieved, because existing infrastructure can be used ([Table 1](#tbl1){ref-type="table"}). For vaccines based on novel technologies, e.g., mRNA, this capacity needs to be built, and this typically takes time. Although it would be beneficial if even a limited number of doses were available to protect health care workers and the most vulnerable segments of the population, the goal should be to make vaccines available to the global population. This will be challenging. Even for influenza virus vaccines, for which many production facilities exist in high-income countries, as well as low- and middle-income countries, the demand in the case of a pandemic would by far exceed the production capacity.

Finally, it takes time to distribute vaccines and administer them. To vaccinate a large proportion of the population would likely take weeks. Given that the population is currently naive to SARS-CoV-2, it is highly likely that more than one dose of the vaccine will be needed. Prime-boost vaccination regimens are typically used in such cases, and the two vaccinations are usually spaced 3--4 weeks apart. It is likely that protective immunity will be achieved only 1--2 weeks after the second vaccination. This therefore adds another 1--2 months to the timeline. Even if shortcuts for several of the steps mentioned earlier can be found, it is unlikely that a vaccine would be available earlier than 6 months after the initiation of clinical trials. Realistically, SARS-CoV-2 vaccines will not be available for another 12--18 months.

What are potential solutions for these long time frames in the future? One possibility is to build production capacity, to be globally distributed if possible, that can be activated in the event of new emerging viruses. From today's perspective, only a few types of viruses are likely to cause respiratory disease that leads to rapid global spread. Surveillance in the animal reservoir paired with virus characterization studies can identify members of virus families that have the potential to cause pandemics. Vaccine candidates using these isolates could then be produced, tested in animals to determine the mechanisms of protection, and tested in humans to establish the safety of the vaccines. It is unlikely that the same viruses that are chosen as vaccine candidates will later cause outbreaks. However, if the vaccine candidate is sufficiently closely related, sequences for the vaccines could be quickly switched and the vaccines for the newly emerging viruses could be swiftly produced and moved to late-stage clinical trials right away (while large-scale production is ramped up globally). In addition, stockpiled vaccines based on the initial candidates could be deployed, even if slightly mismatched to the strain causing the outbreak (a strategy that is currently used for H5 and H7 avian influenza virus vaccines). This would allow a response within a few weeks and could potentially stop a virus locally before it becomes pandemic. An alternative but challenging solution would be the development of broadly protective vaccines that cover whole virus families or genera. This effort is ongoing for influenza viruses ([@bib15]) and could potentially be applied to coronaviruses, or at least betacoronaviruses. Both of these options are costly and require global political will and vision.

Concluding Remarks {#sec1.6}
------------------

Considering the deep dive stock markets have taken in recent weeks and given the expected effect of a pandemic on the economy, funding for vaccine production infrastructure that would allow a swift response to emerging viruses looks like a great investment. However, without a pandemic looming, such investments have rarely been made in the past, except for H5 and H7 subtype influenza viruses. Now would be the right time to consider investing in vaccines against emerging viruses that can lead to loss of human lives and burden the global economy. An investment of a few billion dollars would allow us to have sufficient surveillance, appropriate vaccine candidates, and infrastructure ready that could churn out vaccines for use in the global population quickly and effectively, potentially stopping an emerging virus in its tracks. In addition, we need well-developed emergency plans that allow us to develop, test, produce, and distribute vaccines within weeks, not months or years. This would need tight coordination among pharmaceutical companies, governments, regulatory agencies, and the World Health Organization (WHO), as well as novel and out-of-the-box approaches to cGMP production, release processes, regulatory science, and clinical trial design.

For SARS-CoV-2, vaccines might come too late to affect the first wave of this pandemic. However, they might be useful if additional waves occur later or in a post-pandemic scenario in which SARS-CoV-2 continues to circulate as a seasonal virus. In addition, lessons learned from handling this outbreak will allow us to be better prepared in the future. The viruses will keep coming.
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